GLASGOW, Scotland, October 12, 2018 /PRNewswire/ --
BDD today announced the appointment of Joanne Kelley as Non-executive Director of the Board.
Jo is a Life Sciences Business Development professional and brings an outstanding track record of strategy development, deal preparation and execution to the BDD Board.
During a long, successful career at AstraZeneca, Jo had extensive experience of global commercial and general management. In the role of Vice President of Business Development, Head of Transactions at AstraZeneca, Jo was responsible for a number of transformational deals. She has led all types of transactions including M&A, technology licensing and collaboration arrangements. Jo has received a number of awards recognising her deal making achievements from colleagues and peers including recognition from The Pharmaceutical Licensing Group.
After retiring from AstraZeneca Jo has continued to pursue her passion to support UK innovation. She now works as a Director of Alderley Park Ventures and is a non executive director at UMI3, the innovation company of Manchester University.
Commenting on this appointment, Howard Stevens, Chairman of BDD, said: "I am delighted to welcome Jo to the Board, she brings a broad range of experience to the role, including significant licensing experience. I am certain she will play a big part in BDD's future success as we continue to grow and expand our licensing and collaboration activities."
Commenting on her appointment, Jo said "I am delighted to be joining the Board of BDD at such an exciting time in the company's expansion. BDD is an innovative and ambitious company with a lot to offer pharma partners."
Notes to Editors
BDD Pharma Ltd is a privately-owned drug delivery company specializing in the development of modified and controlled release oral formulations. BDD's OralogiK™ technology is a tablet-in-tablet drug delivery system providing timed release, sustained release and the opportunity for complex bi- and tri-phasic release of one or multiple drugs. The OralogiK™ technology is protected with granted patents in the US, EU and Japan. Supported by investment from Archangels and the Scottish Investment Bank, BDD has in house clinical trial capabilities for the conduct of gamma scintigraphic/ pharmacokinetic studies in humans.
For more information visit www.bddpharma.com.
SOURCE BDD Pharma Ltd